You are now leaving helsinn.com

Please click 'Continue to external site' if you want to continue.

Grant Requests

We are committed to support research studies that advance medical and scientific knowledge about our products, and medical education and research that improves the lives of cancer patients.

Research grant

Helsinn invites the submission of proposals for research studies in line with its therapeutic areas of interest. At Helsinn’s discretion, research support for such studies may be provided.

Mycosis fungoides-type cutaneous T-cell lymphoma (MF-CTCL)

Proposals that advance clinical knowledge on novel uses; support for case study reports will also be considered.

Chemotherapy-induced nausea and vomiting (CINV)

Proposals focused on advancing CINV prophylaxis and treatment including nausea control, breakthrough/refractory use, orally administered cancer therapies, or use with immunotherapy combined with either moderately emetogenic chemotherapy or highly emetogenic chemotherapy.

Privacy Statement

The provision of personal data by you may be necessary where in our legitimate interest in order for us to provide you with the requested services and for the performance of any contractual relationship with you. Because of our commitment to the protection of your personal data, we evaluate our privacy policies and procedures to implement improvements and refinements from time to time. Please read the Privacy and Cookies Policy carefully in order to understand our views and practices regarding your personal data and how we will treat it. The Privacy Policy is also a part of our Terms of Use for the Website.

Submit your research grant proposal

Please complete our online form to begin the grant request process

Begin

Educational Grant

Helsinn Therapeutics (U.S.) Inc. invites proposals for independent educational programs and materials.

Helsinn may provide funding in the form of an Educational Grant to support legitimate educational programs and activities that are in line with our therapeutic areas of interest. Helsinn is committed to funding programs that communicate the most current disease awareness, scientific, and medical information, to the medical and healthcare community to improve patient care. Educational Grant support will be considered for any scientific, educational or professional program, meeting or event that is organized, controlled, and conducted by an independent third party, including but not limited to, accredited and non-accredited medical education (CME and non-CME) for HCPs and/ or patients, disease awareness, or medical conferences. Educational Grants that are awarded should be multi-supported and must be in accordance with Helsinn’s policies, applicable laws and regulations (federal and state), the PhRMA Code, and ACCME for accredited programs.

Proposals for Educational Grant must include a cover letter that states a description of the proposed educational program, including the subject matter, timing, location, proposed audience, expected number of attendees, and start and end date of each activity (if applicable). Additionally, include with the proposal, the amount requested from Helsinn, indication of multi-support, authorized signature, and complete contact information on whom the funds are to be paid with tax ID number and appropriate attachments (e.g., W-9, proposal, invitations, detailed budget, etc).

Funding requests for multi-supported live presentations, written enduring materials, online courses, and conference symposia from organizations (e.g. hospitals, universities, societies, medical-education vendors) will be reviewed and assessed in conjunction with Helsinn’s goal to help physicians and other healthcare professionals to obtain information and insights that contribute to the improvement of patient care in oncology supportive care and therapeutics. Disease states and areas of interest considered can include, but are not limited to, the following:

Chemotherapy Induced Nausea and Vomiting (CINV)

• Burden of disease, risk factors and clinical consequences

• Updates to antiemesis guidelines

• New advancements in delayed, refractory and/or breakthough CINV in moderately emetogenic chemotherapy and/or highly emetogenic chemotherapy

• Multiday use of CINV therapies

• Case-based presentations with multidisciplinary approach

Mycosis Fungoides Cutaneous T-Cell Lymphoma (MF-CTCL)

• Disease awareness, diagnosis and treatment education for dermatologists, derm-oncs, PAs and others

• New advancements in MF-CTCL

Patient Education (in the Helsinn areas of interest)

Please submit all Educational Grant Proposals to: usgrantrequests@helsinn.com